What is the current stock price of Guardant Health, Inc. (GH)?

As of the latest market data, Guardant Health, Inc. (GH) is trading at $127.51. The stock has seen a gain of 6.39% today.

Does Guardant Health, Inc. (GH) pay a dividend?

Based on current data, Guardant Health, Inc. does not have a confirmed active dividend policy.

What is the market cap of Guardant Health, Inc.?

The current market capitalization of Guardant Health, Inc. (GH) is approximately unavailable.

GH

Guardant Health, Inc.·Healthcare

127.51

6.391%(+7.66)

Close Price

130.00

1.953%(+2.49)

After Hours

Last Updated: — ET

52W L: $38.0352W H: $128.00

GH NEWS

investors.com

17h ago

Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged

Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.

gurufocus.com

19h ago

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shieldâ¢ blood test is now included in updated Ameri

businesswire.com

19h ago

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent screening gaps and.

benzinga.com

May 20

Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test

The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.'s (NASDAQ:GH) Guardant360 Liquid CDx test, expanding the company's blood-based comprehensive genomic profiling capabilities for patients with advanced cancer.

investors.com

May 20

Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?

The Food and Drug Administration approved Guardant Health's newest blood cancer test Wednesday, and the stock leaped to a three-month high.

gurufocus.com

May 20

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

1,999

IPO Date

2018-10-04

Beta

1.49

Websiteguardanthealth.com↗